Mayo Clinic - Arizona

Running trials

• Recruiting

  Liver Transplantation From Donors With HIV: Impact on Opportunistic Infections, Cancer, and Long-Term Outcomes (Expanding HOPE Liver)

  NCT07665372· Source

• Recruiting

  Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

  NCT07805954· Phase 3· Source

• Recruiting

  A Phase 1 Study of the Safety and Tolerability of CTX-10726

  NCT07419841· Phase 1· Source

• Recruiting

  Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

  NCT07621718· Phase 3· Source

• Recruiting

  A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

  NCT07428616· Phase 2· Source

• Recruiting

  A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT07450859· Phase 2· Source

• Recruiting

  A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

  NCT07277413· Phase 1· Source

• Recruiting

  A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

  NCT07284758· Phase 2· Source

• Recruiting

  Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

  NCT07096778· Phase 2· Source

• Recruiting

  A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

  NCT07321106· Phase 1· Source

• Recruiting

  Diagnosing Epilepsy To EffeCT Change

  NCT07110337· Source

• Recruiting

  Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up

  NCT07110454· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

  NCT06948448· Phase 2· Source

• Recruiting

  A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

  NCT07070232· Phase 1/2· Source

• Recruiting

  Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

  NCT06972056· Phase 4· Source

• Recruiting

  A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

  NCT06892548· Phase 1/2· Source

• Recruiting

  BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

  NCT06854003· Phase 2· Source

• Recruiting

  Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

  NCT06510374· Phase 3· Source

• Recruiting

  Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

  NCT06567743· Phase 2· Source

• Recruiting

  A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

  NCT06362252· Phase 1/2· Source

• Recruiting

  AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

  NCT06063850· Phase 1/2· Source

• Recruiting

  Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

  NCT05804370· Phase 3· Source

• Recruiting

  Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

  NCT06375044· Phase 1· Source

• Active, not recruiting

  A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

  NCT06346067· Phase 3· Source

• Recruiting

  A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

  NCT06259552· Phase 1· Source

• Active, not recruiting

  Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

  NCT06106308· Phase 2· Source

• Active, not recruiting

  A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

  NCT06260709· Phase 2· Source

• Active, not recruiting

  Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

  NCT05902169· Phase 3· Source

• Active, not recruiting

  HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

  NCT06001385· Phase 2· Source

• Recruiting

  DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

  NCT05882058· Phase 2· Source

• Recruiting

  Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

  NCT05677100· Source

• Recruiting

  Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

  NCT05919511· Source

• Recruiting

  SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

  NCT05303519· Phase 3· Source

• Recruiting

  A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

  NCT05732103· Phase 1/2· Source

• Active, not recruiting

  Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

  NCT05563220· Phase 1/2· Source

• Active, not recruiting

  A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

  NCT05506943· Phase 2/3· Source

• Recruiting

  Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

  NCT05549297· Phase 3· Source

• Recruiting

  Adverse Outcomes and Mortality in Liver Transplant

  NCT05477277· Source

• Recruiting

  (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

  NCT04996875· Phase 2· Source

• Recruiting

  A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

  NCT04929223· Phase 1· Source

• Active, not recruiting

  A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

  NCT04644770· Phase 1· Source

• Active, not recruiting

  A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

  NCT04497844· Phase 3· Source

• Recruiting

  Pancreatic Cancer Early Detection Consortium

  NCT04970056· Source

• Active, not recruiting

  Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)

  NCT04184050· Phase 1· Source

• Active, not recruiting

  MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

  NCT03962543· Phase 2· Source

• Active, not recruiting

  A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

  NCT03748641· Phase 3· Source

• Active, not recruiting

  Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms

  NCT02489539· Source

• Active, not recruiting

  Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial

  NCT02603341· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer5 recruiting
• Pancreatic cancer5 recruiting
• Bladder cancer3 recruiting
• Epilepsy3 recruiting
• Multiple myeloma3 recruiting
• Acute myeloid leukaemia2 recruiting
• Colorectal cancer2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Melanoma2 recruiting
• Myelodysplastic syndromes2 recruiting
• Chronic myeloid leukaemia1 recruiting
• Endometrial cancer1 recruiting
• Glioblastoma1 recruiting
• Head and neck cancer1 recruiting
• Heart failure1 recruiting
• HIV1 recruiting
• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Liver cirrhosis1 recruiting
• Mantle cell lymphoma1 recruiting
• Meningioma1 recruiting
• Mesothelioma1 recruiting
• Migraine1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroendocrine tumours1 recruiting
• Obesity1 recruiting
• Ovarian cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  NCT06790966· Phase 3· Source

• Completed

  Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT06058793· Phase 3· Source

• Terminated

  Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

  NCT05712694· Phase 3· Source

• Terminated

  ADSTILADRIN Early Utilization and Outcomes in the Real World Setting

  NCT06026332· Source

• Completed

  A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

  NCT05712356· Phase 2· Source

• Recruiting

  ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

  NCT05580562· Phase 3· Source

• Completed

  A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma

  NCT05376800· Phase 1· Source

• Terminated

  Oral AMXT 1501 Dicaprate in Combination With IV DFMO

  NCT05500508· Phase 1/2· Source

• Completed

  Study of DF9001 in Patients With Advanced Solid Tumors

  NCT05597839· Phase 1/2· Source

• Completed

  RNS System NAUTILUS Study

  NCT05147571· Source

• Completed

  A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

  NCT05442047· Phase 2· Source

• Completed

  Treatments of Migraine with Triptans in Individuals with Elevated Cardiovascular Risk and in Pregnant Women

  NCT05854992· Source

• Completed

  A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

  NCT05348785· Phase 2· Source

• Terminated

  A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

  NCT05242822· Phase 1· Source

• Terminated

  STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

  NCT04878432· Phase 2· Source

• Completed

  Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05052801· Phase 3· Source

• Terminated

  A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

  NCT04577963· Phase 1/2· Source

• Completed

  A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer

  NCT04702737· Phase 1· Source

• Completed

  Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer

  NCT04499924· Phase 2/3· Source

• Terminated

  CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

  NCT04695977· Phase 2/3· Source

• Terminated

  GORE® CARDIOFORM Septal Occluder Migraine Clinical Study

  NCT04100135· Source

• Completed

  Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

  NCT04471844· Source

• Completed

  A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer

  NCT04322539· Phase 3· Source

• Completed

  MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

  NCT04495621· Phase 1/2· Source

• Completed

  Phase 1 Study of Oral TP-1454

  NCT04328740· Phase 1· Source

• Completed

  CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

  NCT04136171· Phase 3· Source

• Completed

  CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

  NCT03934840· Phase 2· Source

• Completed

  Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

  NCT03781063· Phase 2· Source

• Completed

  Myeloma-Developing Regimens Using Genomics (MyDRUG)

  NCT03732703· Phase 1/2· Source

• Completed

  Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast

  NCT03789162· Source

• Terminated

  A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

  NCT03288545· Phase 1/2· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

  NCT03201965· Phase 3· Source

• Completed

  Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

  NCT03056755· Phase 2· Source

• Recruiting

  Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

  NCT03016819· Phase 3· Source

• Completed

  A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

  NCT02975934· Phase 3· Source

• Completed

  AFPᶜ³³²T in Advanced HCC

  NCT03132792· Phase 1· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

  NCT03011372· Phase 2· Source

• Recruiting

  Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

  NCT03013998· Phase 2/3· Source

• Completed

  TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

  NCT02493530· Phase 1· Source

• Completed

  Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial

  NCT02089217· Source

• Completed

  A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

  NCT02158858· Phase 1/2· Source